Compare KEEL & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KEEL | NTLA |
|---|---|---|
| Founded | N/A | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.6B |
| IPO Year | 2020 | 2016 |
| Metric | KEEL | NTLA |
|---|---|---|
| Price | $3.33 | $12.85 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 23 |
| Target Price | N/A | ★ $20.02 |
| AVG Volume (30 Days) | ★ 35.2M | 3.5M |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.43 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $229,276,000.00 | $67,671,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $62.75 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 72.03 | 16.92 |
| 52 Week Low | $2.96 | $7.95 |
| 52 Week High | $7.37 | $28.24 |
| Indicator | KEEL | NTLA |
|---|---|---|
| Relative Strength Index (RSI) | 38.58 | 56.22 |
| Support Level | $3.23 | $11.55 |
| Resistance Level | $3.92 | $15.52 |
| Average True Range (ATR) | 0.36 | 0.61 |
| MACD | 0.02 | 0.28 |
| Stochastic Oscillator | 23.36 | 85.61 |
Keel Infrastructure Corp is a North American digital infrastructure and energy company that develops and owns data centers and energy infrastructure for high-performance computing workloads, including AI. The group has a pipeline of 2.2 gigawatts and established grid interconnections already in place. It delivers scalable infrastructure solutions in high-demand power markets across Pennsylvania and Washington in the United States, and Quebec in Canada. It has data campuses in Moses Lake, Panther Creek, Sharon, Sherbrooke, and Scrubgrass.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.